


## Proclamation Request Form

Request for the issuance of proclamations is governed by Council Policy. Requests are recommended **2 months** in advance of the requested issuance date and may be emailed [ClerksApprovalRequests@london.ca](mailto:ClerksApprovalRequests@london.ca) or mailed to City Hall, P.O. Box 5035 London, ON N6A 4L9.

<u>Name of Organization</u> London Run for Ovarian Cancer
<u>Proclamation Name</u> London Run for Ovarian Cancer Week
<u>Date of Proclamation Requested</u> May 6-12, 2024
<u>Proclamation Type</u> (day, week or month) Week
<b>Organization's Direct Connection to London</b> (provide specific details) The London Run for Ovarian Cancer is a charitable run/walk held every Mother's Day to raise funds for research on ovarian cancer being conducted here in London at the LHSC Cancer Clinic. This will be the 22nd run, and we have raised more than \$2 million over the first 21 years. The event is run by volunteers and attracts approximately 400 participants each year. The event receives corporate sponsorship donations from many London businesses, which are used to cover the costs of the run. Ovarian cancer is the deadliest women's cancer, with just 30% of women who are diagnosed surviving for five years. We desperately need more research to improve early diagnosis and subsequent treatment.
<u>Required Supporting Documents:</u> <input checked="" type="checkbox"/> Detail information on the Organization } <i>see "LRFOC Fact Sheet 2022"</i> <input checked="" type="checkbox"/> Detail information on the Event <input checked="" type="checkbox"/> Confirmation of authorization from the Organization to submit request <i>Below</i>
<u>Category</u> (public awareness campaigns, charitable funding campaigns, arts and cultural celebrations) Charitable funding event
<u>Requester Name</u> James Olson, Chair, Executive Committee, London Run for Ovarian Cancer
<u>Requester Address</u> [REDACTED] London, Ontario N6E 2A2
<u>Requester Phone Number and Email</u> [REDACTED]
The undersigned confirms that I am the Official Representative of the Organization requesting the Proclamation and that by signing this Application, I acknowledge and agree that my organization complies with all City of London's Policies and By-laws.
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;">                       _____                      Signature                 </div> <div style="width: 45%; text-align: right;">                     April 28, 2024                      _____                      Date                 </div> </div>
Notice of collection of personal information Personal information collected on this form is collected under the authority of the <i>Municipal Act, 2001</i> , S.O. 2001, c. 25 and may also be used for purposes related to the Issuance of Proclamations Policy and Proclamation Request Form. Questions about this collection should be addressed to Manager, Records and Information Services, 3rd floor, City Hall, 300 Dufferin Ave., London, ON N6A 4L9. Tel: 519-661-2489 ext. 5590, email: <a href="mailto:eskalski@london.ca">eskalski@london.ca</a> .



Local run has  
raised over \$2.5 million in  
19 years!

[www.runforovariancancer.ca](http://www.runforovariancancer.ca)

**Next run Mother's Day, Sunday, May 8, 2022**

Now in its 20th year, the London Run for Ovarian Cancer, supported by London Health Sciences Foundation, generates the largest amount of funding for LHSC of any volunteer group in London – more than \$2.5 million to date – all with only a one-day event!

**Help us raise even more this year.**

Ovarian cancer is the fifth-ranking cause of cancer deaths for women with about 2,800 women diagnosed each year in Canada. Even so, only 2.1 per cent of Canadians' donations for cancer research is directed toward ovarian cancer. That's because the disease leaves few survivors to advocate and raise funds.

Ovarian cancer is called the silent killer. Unlike other cancers, there is no screening test and there are few obvious symptoms to this cancer. As a result, by the time most cases are diagnosed, the patients are at stages three or four, and at that late stage, 70 per cent of those diagnosed will die. London Health Sciences researchers and clinicians are working to change those statistics.

### **London Regional Cancer Program**

London Regional Cancer Program (LRCP) is the home of cancer treatment, education and research at London Health Sciences Centre (LHSC), serving over one million people in Southwestern Ontario at Victoria Hospital.

Through its unique research initiatives, LRCP is recognized internationally for its innovative basic, clinical and translational cancer research – the transfer and advancement of knowledge from basic research through to implementation of new clinical practices – in cancer biology, new therapeutics and cancer imaging.

***“We want the community to realize we appreciate the support that we have. It is absolutely essential for us to continue our pace of ground-breaking research.” Dr. Trevor Shepherd***

### **Translational Ovarian Cancer Research Program**

The Translational Ovarian Cancer Research Program (TOCRP) was initiated in 2007 with the recruitment of Dr. Trevor Shepherd, who was appointed the first Translational Oncology Scientist of the LHSC and Cancer Research Laboratory Program (CRLP). Dr. Shepherd brought considerable expertise in ovarian cancer research. He and Dr. Gabriel DiMattia, Senior Oncology Scientist, co-lead the TOCRP to develop research projects that will impact the health of ovarian cancer patients. This research group works alongside LRCP gynecologic cancer surgeons – Doctors Bertrand, McGee, Préfontaine and Sugimoto – who provide clinical input and essential material needed to conduct research.

## Current research initiatives

Dr. Trevor Shepherd, Co-Lead of the Translational Ovarian Cancer Research Unit (TOCRU), has made breakthrough discoveries related to the metabolism of ovarian cancer cells. Dr. Shepherd chose the key “energy stress” enzyme called LKB1 as a potential therapeutic target because it helps ovarian cancer survive during spread of disease. He credits the London Run for Ovarian Cancer with providing funding that was critical to obtain information needed for his successful grant from the Canadian Institutes of Health Research. From this funded study, his team has exciting new evidence demonstrating that blocking LKB1 activity in ovarian tumours reduced the ability for cancer cells to spread. Over the past few years, he has established new collaborations with researchers at the Ontario Institute of Cancer Research in Toronto to apply innovative molecular approaches to therapeutically reduce cancer cell ability to evade the effects of chemotherapeutic drugs.

Ovarian cancer patients often accumulate fluid in the belly (ascites) that can lead to the spread of the disease because it contains cancer cells. These cells often form floating clusters or spheroids that are thought to be responsible for the spread of ovarian cancer. Proceeds from the [London Run for Ovarian Cancer](#) have supported the establishment of a biobank that has received more than 400 patient samples over the last 13 years.

Dr. G. DiMattia, Co-Lead of the TOCRU, uses these ascites samples to develop new models of ovarian cancer in the form of immortalized cell lines. These are the most essential and fundamental tools cancer researchers use worldwide. This work has led to the development of new cell lines from rarer forms of ovarian cancer that weren't previously available. Dr. DiMattia has developed a number of cell lines from women battling low-grade ovarian cancer for which there are few treatments. In collaboration with Dr. Mark Carey, University of British Columbia Gynecologic Oncology Surgeon, they developed the first model of low-grade ovarian cancer and are endeavouring to generate more models necessary to develop and test new drugs to treat this form of ovarian cancer. Dr. DiMattia has developed numerous collaborations with other scientists both locally and around the world to utilize these new cell lines in the collective fight against ovarian cancer.

## You can help – it's money well spent

People who financially support the cause of overcoming ovarian cancer – “the most lethal women's cancer” – have a “moderate to high donor opportunity for impact,” according to a recent research report *Cancer in Canada*, conducted by Charity Intelligence Canada.

The London Run for Ovarian Cancer was initiated in 2003 by a London woman, Ann Crowley, after she was diagnosed with Stage III ovarian cancer. In the first year, Ann with the support of friends and family raised \$85,000 and dedicated all funds raised by runners and their supporters to research focused on early detection and to discovering a cure for ovarian cancer. Since her death later in 2003, Ann's friends have continued her quest. Since 2006, the funds raised have gone directly to the Translational Ovarian Cancer Research Program.

Each year, more people from across the London region are joining this grassroots volunteer organization in the challenge to conquer this stealthy disease.

**We would be delighted to include you on our team. Help us to make a difference and create the moments that have the power to change and save lives.**